PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients-Reference-Cited by-同舟云学术

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

Published:2009-01 Issue:1 Volume:20 Page:84-90
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Perrone F.,Lampis A.,Orsenigo M.,Di Bartolomeo M.,Gevorgyan A.,Losa M.,Frattini M.,Riva C.,Andreola S.,Bajetta E.,Bertario L.,Leo E.,Pierotti M.A.,Pilotti S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/1/84/307603/mdn541.pdf

Reference27 articles.

1. Cetuximab for treatment of colorectal cancer;Jonker;N Engl J Med,2007

2. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients;Frattini;Br J Cancer,2007

3. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab;Lièvre;J Clin Oncol,2008

4. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry;Chung;J Clin Oncol,2005

5. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer;Hebbar;Anticancer Drugs,2006

Cited by 355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

2. Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data;ESMO Real World Data and Digital Oncology;2024-06

3. PTEN and P-4E-BP1 might be associated with postoperative recurrence of rectal cancer patients undergoing concurrent radiochemotherapy;BMC Cancer;2024-05-13

4. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration;Biology Direct;2024-05-07

5. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212);Clinical Cancer Research;2024-01-30